Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Madrigal Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Madrigal Pharmaceuticals kazanç ve gelirin sırasıyla yıllık 68.1% ve 56.1% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 68.1% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -163.5% olacağı tahmin edilmektedir.

Anahtar bilgiler

68.1%

Kazanç büyüme oranı

68.1%

EPS büyüme oranı

Biotechs kazanç büyümesi	28.8%
Gelir büyüme oranı	56.1%
Gelecekteki özkaynak getirisi	-163.5%
Analist kapsamı	Good
Son güncelleme	04 Oct 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Broker Revenue Forecasts For Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Are Surging Higher

Aug 09

Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge

Mar 15

Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's Potential

Feb 07

Calculating The Intrinsic Value Of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

Dec 20

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Aug 05

Madrigal: Buy And Hoard Before Q4 Data Readout

Aug 04

Madrigal cut to Neutral at B. Riley on concerns over upcoming NASH readout

Jul 08

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Could Be 45% Below Their Intrinsic Value Estimate

May 11

Madrigal: NASH Data In Q4 Is The Key

Apr 19

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Feb 24

Madrigal: Delayed NASH Data Is Positive But Real Tests Are Still To Come

Jan 31

Madrigal: Powerful Catalyst Approaching

Jan 09

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Nov 08

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Jul 26

Madrigal Pharmaceuticals: Leading The NASH Innovation

May 05

Here's Why We're Watching Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Situation

Apr 12

We Think Madrigal Pharmaceuticals (NASDAQ:MDGL) Can Afford To Drive Business Growth

Dec 28

Madrigal Pharma: A Look At The Early MAESTRO Trial Data

Nov 27

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:MDGL - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	937	116	-77	-129	13
12/31/2025	473	-407	-374	-481	16
12/31/2024	101	-615	-509	-540	16
6/30/2024	15	-510	-456	-449	N/A
3/31/2024	N/A	-444	-391	-389	N/A
12/31/2023	N/A	-374	-326	-324	N/A
9/30/2023	N/A	-347	-303	-303	N/A
6/30/2023	N/A	-330	-277	-277	N/A
3/31/2023	N/A	-315	-259	-259	N/A
12/31/2022	N/A	-295	-225	-225	N/A
9/30/2022	N/A	-274	-215	-214	N/A
6/30/2022	N/A	-256	-201	-201	N/A
3/31/2022	N/A	-247	-191	-190	N/A
12/31/2021	N/A	-242	-184	-184	N/A
9/30/2021	N/A	-236	-191	-191	N/A
6/30/2021	N/A	-231	-193	-193	N/A
3/31/2021	N/A	-219	-171	-170	N/A
12/31/2020	N/A	-202	-158	-158	N/A
9/30/2020	N/A	-171	-115	-115	N/A
6/30/2020	N/A	-134	-79	-78	N/A
3/31/2020	N/A	-105	-66	-66	N/A
12/31/2019	N/A	-84	-42	-42	N/A
9/30/2019	N/A	-68	-36	-36	N/A
6/30/2019	N/A	-55	-30	-30	N/A
3/31/2019	N/A	-42	-23	-23	N/A
12/31/2018	N/A	-33	-26	-26	N/A
9/30/2018	N/A	-30	-25	-25	N/A
6/30/2018	N/A	-30	-25	-25	N/A
3/31/2018	N/A	-32	N/A	-27	N/A
12/31/2017	N/A	-31	N/A	-22	N/A
9/30/2017	N/A	-30	N/A	-22	N/A
6/30/2017	N/A	-36	N/A	-26	N/A
3/31/2017	N/A	-31	N/A	-21	N/A
12/31/2016	N/A	-26	N/A	-18	N/A
9/30/2016	N/A	-21	N/A	-13	N/A
6/30/2016	N/A	-8	N/A	-5	N/A
3/31/2016	N/A	-7	N/A	-3	N/A
12/31/2015	N/A	-7	N/A	-3	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: MDGL önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.5% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: MDGL önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: MDGL önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: MDGL şirketinin gelirinin (yıllık 56.1% ) US pazarından (yıllık 8.7% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: MDGL şirketinin gelirinin (yıllık 56.1% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: MDGL 3 yıl içinde kârsız olması bekleniyor.

Madrigal Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus revenue estimates increase by 34%, EPS downgraded

Forecast to breakeven in 2026

No longer forecast to breakeven

Consensus EPS estimates fall by 11%

Price target increased by 18% to US$383

Consensus revenue estimates fall by 14%

Recent updates

Madrigal Pharmaceuticals, Inc. Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development

CEO, President & Director recently sold US$1.6m worth of stock

CEO, President & Director notifies of intention to sell stock

Consensus revenue estimates increase by 34%, EPS downgraded

Broker Revenue Forecasts For Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Are Surging Higher

While Madrigal's Rezdiffra Impresses, Great Uncertainties Loom In MASH Market

Madrigal Pharmaceuticals, Inc. Appoints Shannon Kelley as General Counsel

Madrigal Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Madrigal May Not Be Able To Shrug GLP-1 Drugs For Long

Madrigal Pharmaceuticals, Inc. Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra (resmetirom) Presented at the EASL Congress

Independent Lead Director notifies of intention to sell stock

Forecast to breakeven in 2026

No longer forecast to breakeven

Madrigal Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Madrigal Pharmaceuticals, Inc., Annual General Meeting, Jun 25, 2024

Madrigal Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage

Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis

Independent Director notifies of intention to sell stock

Madrigal Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $599.999764 million.

Madrigal Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $599.999764 million.

Consensus EPS estimates fall by 11%

Price target increased by 18% to US$383

Madrigal Pharmaceuticals, Inc. Announces FDA Approval of Rezdiffra™ (Resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (Nash) with Moderate to Advanced Liver Fibrosis

Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge

Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis

Madrigal Pharmaceuticals, Inc. Announces Management Changes

Madrigal Pharmaceuticals, Inc. Appoints CFO Changes

Consensus revenue estimates fall by 14%

Forecast breakeven date pushed back to 2026

New minor risk - Share price stability

Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine

Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's Potential

Madrigal Pharmaceuticals, Inc. Announces Additions to its Leadership Team

Insider exercised options and sold US$513k worth of stock

Senior VP & General Counsel exercised options and sold US$894k worth of stock

Madrigal Pharmaceuticals, Inc. Appoints Ronald Filippo as Chief Information Officer

Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer

New major risk - Financial position

Madrigal Pharmaceuticals, Inc. Announces the Resignation of Remy Sukhija as Chief Commercial Officer

Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of Nash with Liver

Madrigal Pharmaceuticals, Inc. Announces Chief Executive Officer Changes

Madrigal Pharmaceuticals, Inc. Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis

Price target increased by 7.4% to US$341

Insider exercised options and sold US$1.9m worth of stock

Consensus revenue estimates fall by 92%

Independent Director exercised options and sold US$4.3m worth of stock

Senior VP & General Counsel exercised options and sold US$2.5m worth of stock

Madrigal Pharmaceuticals, Inc. Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of Nash with Liver Fibrosis

Forecast to breakeven in 2025

Madrigal Pharmaceuticals, Inc. announced that it has received $90 million in funding

Madrigal Pharmaceuticals, Inc. Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis

Calculating The Intrinsic Value Of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

Price target increased to US$164

Insufficient new directors

Madrigal Pharmaceuticals Initiates the MAESTRO-NASH Outcomes Study Evaluating Resmetirom for the Treatment of Patients with Compensated NASH Cirrhosis

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Madrigal: Buy And Hoard Before Q4 Data Readout

Madrigal cut to Neutral at B. Riley on concerns over upcoming NASH readout

Madrigal Pharmaceuticals, Inc. Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Could Be 45% Below Their Intrinsic Value Estimate

Madrigal Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022

Insufficient new directors

Madrigal: NASH Data In Q4 Is The Key

Madrigal Pharmaceuticals Provides Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financial Results

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Madrigal Pharmaceuticals, Inc. Announces Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistically Significant Improvements in Key Measures of Liver and Cardiovascular Health

Madrigal: Delayed NASH Data Is Positive But Real Tests Are Still To Come

Madrigal Pharmaceuticals to Announce Topline Results from the Phase 3 MAESTRO-NAFLD-1 Study of Resmetirom